Literature DB >> 23186064

Expression of decoy receptor 3 in diffuse sclerosing variant of papillary thyroid carcinoma: correlation with M2 macrophage differentiation and lymphatic invasion.

Wei-Chin Chang1, Jui-Yu Chen, Chen-Hsen Lee, An-Hang Yang.   

Abstract

BACKGROUND: The diffuse sclerosing variant of papillary thyroid carcinoma (DSV-PTC) is a unique variant of PTC that is characterized by extensive lymphovascular invasion of tumor cells in a background of lymphocytic thyroiditis. The lymphatic emboli contain tumor cells as well as macrophages, but the recruitment of these macrophages is not well understood. The aim of this study was to determine the relationship between the expression of Decoy receptor 3 (DcR3), the recruitment of tumor-associated macrophages (TAMs), and lymphatic invasion in DSV-PTC.
METHODS: We retrospectively examined 14 cases of DSV-PTC using immunohistochemistry studies. The density of TAMs, lymphatic vessel density, lymphatic invasion, tumor emboli area, and DcR3 expression were assessed. Statistical analyses were performed using Fisher's exact test, unpaired t-test, and linear regression.
RESULTS: The lymphatic tumor emboli contained a relatively higher density of TAMs than stroma and classical PTC (CPTC) areas. In addition, the number of lymphatic invasions and the size of the tumor emboli area were positively correlated with the number of M2 TAMs. A higher density of M2 TAMs was associated with older patients and larger tumor size. Moreover, DcR3 was expressed only in lymphatic tumor cells and squamous metaplastic tumor cells, but not in macrophages and CPTC. In addition, the preferential expression of DcR3 in tumors was associated with higher levels of M2 TAMs and lymphatic invasion.
CONCLUSION: Despite the fact that the exact relationship between DcR3, M2 macrophages, and lymphatic invasion in DSV-PTC remains to be elucidated, our findings suggest that DcR3 expression in DSV-PTC tumor cells may promote the polarized macrophage differentiation toward the M2 phenotype. This phenomenon may further promote lymphatic invasion of DSV-PTC tumor cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23186064      PMCID: PMC3675829          DOI: 10.1089/thy.2012.0261

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  24 in total

1.  Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.

Authors:  Huixiang Li; Lurong Zhang; Hong Lou; Ivan Ding; Sunghee Kim; Luping Wang; Jiaoti Huang; P Anthony Di Sant'Agnese; Jun-Yi Lei
Journal:  Am J Clin Pathol       Date:  2005-08       Impact factor: 2.493

2.  Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage.

Authors:  TuDung T Nguyen; Erich J Schwartz; Robert B West; Roger A Warnke; Daniel A Arber; Yasodha Natkunam
Journal:  Am J Surg Pathol       Date:  2005-05       Impact factor: 6.394

3.  Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.

Authors:  Sunghee Kim; Anastasia Fotiadu; Vassiliki Kotoula
Journal:  Clin Immunol       Date:  2005-06       Impact factor: 3.969

4.  CD163: a specific marker of macrophages in paraffin-embedded tissue samples.

Authors:  Sean K Lau; Peiguo G Chu; Lawrence M Weiss
Journal:  Am J Clin Pathol       Date:  2004-11       Impact factor: 2.493

5.  Decoy receptor 3 is a prognostic factor in renal cell cancer.

Authors:  Stephan Macher-Goeppinger; Sebastian Aulmann; Nina Wagener; Benjamin Funke; Katrin E Tagscherer; Axel Haferkamp; Markus Hohenfellner; Sunghee Kim; Frank Autschbach; Peter Schirmacher; Wilfried Roth
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

6.  Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3.

Authors:  Yung-Chi Chang; Tse-Ching Chen; Chun-Ting Lee; Chih-Ya Yang; Hsei-Wei Wang; Chao-Ching Wang; Shie-Liang Hsieh
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

7.  A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors.

Authors:  Jeffrey Wyckoff; Weigang Wang; Elaine Y Lin; Yarong Wang; Fiona Pixley; E Richard Stanley; Thomas Graf; Jeffrey W Pollard; Jeffrey Segall; John Condeelis
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

8.  The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.

Authors:  Yasushi Takahama; Yukishige Yamada; Koji Emoto; Heisuke Fujimoto; Tomoyoshi Takayama; Masatoh Ueno; Hideki Uchida; Shuya Hirao; Takashi Mizuno; Yoshiyuki Nakajima
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

9.  Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer.

Authors:  Mabel Ryder; Ronald A Ghossein; Julio C M Ricarte-Filho; Jeffrey A Knauf; James A Fagin
Journal:  Endocr Relat Cancer       Date:  2008-08-21       Impact factor: 5.678

10.  Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma.

Authors:  Bernard Caillou; Monique Talbot; Urbain Weyemi; Catherine Pioche-Durieu; Abir Al Ghuzlan; Jean Michel Bidart; Salem Chouaib; Martin Schlumberger; Corinne Dupuy
Journal:  PLoS One       Date:  2011-07-21       Impact factor: 3.240

View more
  7 in total

Review 1.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

Review 2.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

Review 3.  Decoy receptor 3: an endogenous immunomodulator in cancer growth and inflammatory reactions.

Authors:  Shie-Liang Hsieh; Wan-Wan Lin
Journal:  J Biomed Sci       Date:  2017-06-19       Impact factor: 8.410

4.  Bleomycin inhibits proliferation and induces apoptosis in TPC-1 cells through reversing M2-macrophages polarization.

Authors:  Hongwei Liu; Huilei Dong; Li Jiang; Zhendong Li; Xiande Ma
Journal:  Oncol Lett       Date:  2018-07-06       Impact factor: 2.967

Review 5.  The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.

Authors:  Gilda Varricchi; Stefania Loffredo; Giancarlo Marone; Luca Modestino; Poupak Fallahi; Silvia Martina Ferrari; Amato de Paulis; Alessandro Antonelli; Maria Rosaria Galdiero
Journal:  Int J Mol Sci       Date:  2019-08-13       Impact factor: 5.923

6.  Potential role of M2 TAMs around lymphatic vessels during lymphatic invasion in papillary thyroid carcinoma.

Authors:  Takanobu Kabasawa; Rintaro Ohe; Naing Ye Aung; Yuka Urano; Takumi Kitaoka; Nobuyuki Tamazawa; Aya Utsunomiya; Mitsunori Yamakawa
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

7.  Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.

Authors:  Zhenyu Xie; Xin Li; Yuzhen He; Song Wu; Shiyue Wang; Jianjian Sun; Yuchen He; Yu Lun; Jian Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.